Objective: Candida infections cause substantial morbidity and mortality in neonates. Persistent candidemia has not been associated with increased risk of mortality compared with candidemia of shorter duration. This study sought to determine whether persistent candidemia was associated with increased length of hospitalization or mortality in neonates.
Introduction
Candida infections are the third most common cause of late-onset sepsis in very-low-birth weight infants in the neonatal intensive care unit (NICU). 1 They are a significant source of infant morbidity and mortality, and may also affect neurodevelopmental outcomes. 2, 3 Neonatal candidemia can result in disseminated infection and increase the length and cost of hospitalization. 4 In a National Institute of Child Health and Human Development Neonatal Research Network Study, antifungal therapy failure (defined as death within 14 days after initiation of antifungal therapy or a positive blood culture for Candida species beyond the 14-day period) was observed in 26% of extremely low-birth weight infants. 3 The median number of days of positive blood cultures after systemic antifungal therapy was 3 days for infants who survived, and 10% had candidemia for X14 days. Neurodevelopmental disability and death were associated with delayed catheter removal when controlling for gestational age, gender and center.
This study sought to determine whether increased duration of candidemia was associated with increased length of hospitalization and increased mortality in neonates. Furthermore, multiple factors were analyzed to determine association with persistent candidemia.
Methods
A retrospective review of Candida bloodstream infections of patients in the NICU at a tertiary care teaching hospital in Wichita, Kansas, USA, from 1 January 2000 to 31 December 2010, was performed. A blood culture that grew any Candida species was defined as a candidemia episode. Recurrent candidemia was defined as two negative peripheral blood cultures in between incidents of Candida-positive blood cultures. For the purposes of this study, a subsequent candidemia episode was not included in the statistical analysis. Based on the study by Levy et al. 5 persistent candidemia was defined as a positive culture for >5 days.
Two separate sources comprise the database that was interrogated for initial data collection: (1) Meditech, the comprehensive records system utilized by the hospital, containing all laboratory, pharmacy and discharge data; and (2) the neonatal data warehouse derived from the NICU documentation software, which was created and maintained by the hospital. The database was queried for the following information from each patient: birth weight, gestational age, method of delivery (vaginal versus Cesarean section) and laboratory data to determine onset and duration of positive cultures for Candida species (calendar days and not 24 h periods), as well as the presence of a central venous catheter and a positive cerebrospinal fluid or urine culture for Candida species. Laboratory data also contained the lowest and highest blood glucose levels on the day of or the day before the first blood culture that grew a Candida species, plus the lowest platelet count within 1 day of the initial positive blood culture. Nutritional data included the number of days that hyperalimentation and enteral feedings were administered before the initial positive blood culture. Pharmacy data were used to determine the choice and duration of initial antifungal treatment, and the number of days other antimicrobial agents were administered in the 4 weeks before the initial positive blood culture. The presence of Candida dermatitis was determined from use of a topical antifungal (nystatin or clotrimazole) in the 7 days before the initial positive blood culture. From the discharge information, outcomesFthat is, mortality status at hospital discharge and overall length of hospitalizationFwere elicited. Information not available from electronic queries was obtained by review of patient paper charts.
STATA for Macintosh (version 11.1; StataCorp, College Station, Texas, USA) statistical software was utilized for data analysis. Univariate methods (contingency table analysis and logistic regression) were applied to independent variables associated with the dependent binary variables of persistent candidemia and mortality. Variables analyzed were birth weight, gestational age, age in days at time of infection, hyperalimentation, enteral feeds, Candida species, presence of central venous catheter and if present days until the catheter was removed, antifungal agent and days of antibiotics before infection. Multivariate logistic regression modeling was reserved for use in analyzing binary outcome measures (persistent candidemia and mortality) with risk factors found to be statistically significant by univariate analysis and to control for potential confounding by variables such as birth weight, gestational age and presence of a central venous catheter. The relationship between length of hospitalization and persistent candidemia was assessed with nonparametric testing (k-sample equality of medians test). Statistical significance was defined as a P-value p0.05.
All patient data were de-identified and assigned a case identification number for this study. The study was approved by the Human Subjects Committee at the University of Kansas School of Medicine-Wichita and the Institutional Review Board of the Wichita Medical Research and Education Foundation.
Results
During the 11-year period of study, 8199 patients were admitted to the NICU. Of these, 37 (0.45%) were found to have at least one positive blood culture for Candida species. There were 710 infants admitted to the NICU during the study period with a birth weight of <1000 g and 24 had candidemia (3.4%). Two (5%) of the 37 patients had a recurrent episode of candidemia identified, and the subsequent episode was not included in the data analysis. Of the 37 patients, one could not be categorized as having either persistent or non-persistent candidemia because mortality occurred before a repeat blood culture could be obtained. Nine (24%) of the 37 patients were found to have persistent candidemia.
Candida albicans was the most prevalent species identified (59%, n ¼ 22), with Candida parapsilosis (24%, n ¼ 9), Candida tropicalis (8%, n ¼ 3) and Candida lusitaniae (5%, n ¼ 2) following in incidence. For the one remaining patient, the microbiology laboratory identified 'Candida species' on culture. Two patients also had a urine culture that grew the same Candida species as the blood culture, but no patient had a positive cerebrospinal fluid culture. Amphotericin B was the initial antifungal used for 33 patients (89%), fluconazole for 3 patients (8%) and 1 patient received both amphotericin B and fluconazole (3%).
There was no difference in length of hospitalization between the groups with and without persistent candidemia (P ¼ 0.74) (Figure 1 ). Of the five deaths before hospital discharge (14%), four were attributed to active candidemia based on review of neonatologist mortality summaries and external autopsy reports. Of these four, all died within 5 days of the first positive blood culture (mean of 3 days). The other death, attributed to necrotizing enterocolitis, occurred 2 weeks after a 15-day period of persistent positive blood cultures. Therefore, no patients died as a direct consequence of persistent candidemia. Among the 37 patients with candidemia, no cases of Candida endocarditis were identified. The number of days between the first positive culture collection and the initial dose of antifungal therapy was associated with persistent candidemia (P ¼ 0.03) ( Table 1) . Most patients who developed persistent candidemia (67%, n ¼ 6) had >1 day between first positive culture collection and the start of antifungal therapy compared with only 13% (n ¼ (Table 1) .
All days during which a patient received nutrition by hyperalimentation before the first positive blood culture for Candida were counted, as were the days when the patient was fed enterally. A ratio (all prior enteral feeding days to all prior hyperalimentation days) was calculated for each patient. A decrease in this ratio was significantly associated with an increase in all-cause mortality (P ¼ 0.03) and death attributed to candidemia (P ¼ 0.04) (Figure 2) . Likewise, the risk of all-cause mortality was decreased with a history of having received any enteral feedings before the first positive blood culture (P ¼ 0.04; risk ratio ¼ 0.18, 95% CI: 0.04-0.92), as was death attributed to candidemia (P ¼ 0.02; risk ratio ¼ 0.09, 95% CI: 0.01-0.77). By univariate analysis gestational age, birth weight, age at the time of infection, Candida species, presence of a central venous catheter at the time of infection, time to catheter removal and initial antifungal choice were not significantly associated with all-cause mortality or mortality attributed to candidemia.
Discussion
Levy et al. 5 examined the effect of persistent candidemia (that is, positive blood culture for Candida species for >5 days) versus non-persistent candidemia on morbidity and mortality. They did find an increased incidence of endocarditis with persistent candidemia, but no increase in mortality. We too did not note an increase in mortality with persistent candidemia. We did not identify any patients with endocarditis. In contrast, Chapman et al. 6 recognized an increased rate of focal complications and death in patients who had a positive repeat culture from a sterile site (urine, cerebrospinal fluid, blood or any other normally sterile site) >24 h after achieving target doses of amphotericin B or fluconazole. Natarajan et al. 7 reported greater mortality in infants with refractory candidemia (defined as continuous positive blood cultures for Candida species between 48 and 72 h following treatment with both amphotericin B and fluconazole) compared with those who responded to these initial therapies. These disparate results may reflect a difference in the definition of persistent or prolonged candidiasis and the role of infections outside the bloodstream.
In our study, no deaths were attributed to persistent candidemia; all four Candida-related deaths occurred quickly within 5 days of initial positive blood cultures for Candida species. This underscores the importance of prevention, prompt recognition and optimal treatment, including prompt central line removal, of invasive candidiasis. 3, 6, 8, 9 The decision to begin empiric therapy (a modifiable risk factor) may have prevented persistent candidemia. In a majority of the cases of persistent candidemia (67%, n ¼ 6), treatment initiation followed initial culture collection by at least 1 day.
In a 2009 clinical practice guideline, the Infectious Diseases Society of America supported routine prophylactic treatment for premature infants and extremely low-birth weight infants in hospitals with a high incidence of neonatal candidiasis. 8, 10 Notably, the site of this study has a low incidence by internal measure (3% for birth weight under 1000 grams); thus, fungal prophylaxis would not be indicated.
It has been suggested that empiric therapy, if employed, could be based on systematic risk factor modeling; 10 however, a benefit in outcome, specifically mortality, has not been substantiated to date in a prospective randomized study. A single center retrospective study with historical controls did note a reduction in mortality after adopting an institutional guideline for initiating antifungal therapy. 9 Benjamin et al. 10 identified the following as risk factors for the development of invasive candidiasis: vaginal delivery, lower gestational age at delivery, Candida dermatitis, presence of a central catheter, lack of enteral feeds, increased blood glucose, increased number of antibiotic days and decreased platelet count. From the present study, utilization of a clinical prediction modelFas discussed by Benjamin et al. 10 Fcould have resulted in five of the six persistent candidemia patients receiving empiric antifungal therapy, as they had at least three of the risk factors above. We believe these findings justify further study of a clinical checklist for initiating empiric antifungal therapy.
Two factors distinguished outcome for all of the neonates with candidemia. One, the ratio of total enteral feeding to hyperalimentation days before the first positive culture has not been previously described in the literature. The ratio was created to describe the balance between the two modes of nutrition. This ratio was not associated with the development of persistent candidemia; the same was true for the history of having received any enteral feedings before candidemia. In contrast, these two variables were independently associated with a decreased risk of both Candida-related death and all-cause mortality. Broadly speaking, the absence of enteral feeds could be reflective of the severity of illness in those patients rather than a predisposing factor itself. 2, 3, 10, 11 The limitations of this study include the retrospective design and the size of the study population. Other authors on this topic have cited the constraints of single center study. 2 By replicating the work of previous authors, 5 this investigation enhances the generalizability of these results and demonstrates that persistent candidemia is not associated with increased duration of hospital stay or increased mortality, as the infants who died from Candidarelated causes did so within 5 days of the first positive blood culture.
This study implies that a duration of >1 day between the collection of the first positive blood culture and the initial dose of systemic antifungal treatment places neonates at increased risk for developing persistent candidemia. At a center with a low rate of infection, Candida prophylaxis has not been not recommended; however, empiric treatment utilizing a risk-based clinical checklist may decrease the duration of candidemia for selected high-risk infants with suspected sepsis.
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